These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25615959)

  • 1. Interleukin-6 and tumor necrosis factor-α are associated with quality of life-related symptoms in pulmonary arterial hypertension.
    Matura LA; Ventetuolo CE; Palevsky HI; Lederer DJ; Horn EM; Mathai SC; Pinder D; Archer-Chicko C; Bagiella E; Roberts KE; Tracy RP; Hassoun PM; Girgis RE; Kawut SM
    Ann Am Thorac Soc; 2015 Mar; 12(3):370-5. PubMed ID: 25615959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design of a phase II clinical trial of aspirin and simvastatin for the treatment of pulmonary arterial hypertension: ASA-STAT.
    Kawut SM; Bagiella E; Shimbo D; Lederer DJ; Al-Naamani N; Roberts KE; Barr RG; Post W; Horn EM; Tracy R; Hassoun P; Girgis R;
    Contemp Clin Trials; 2011 Mar; 32(2):280-7. PubMed ID: 21146637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Significance of Biomarkers in Pulmonary Arterial Hypertension.
    Al-Naamani N; Palevsky HI; Lederer DJ; Horn EM; Mathai SC; Roberts KE; Tracy RP; Hassoun PM; Girgis RE; Shimbo D; Post WS; Kawut SM;
    Ann Am Thorac Soc; 2016 Jan; 13(1):25-30. PubMed ID: 26501464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ferritin levels, inflammatory biomarkers, and mortality in peripheral arterial disease: a substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) Trial.
    Depalma RG; Hayes VW; Chow BK; Shamayeva G; May PE; Zacharski LR
    J Vasc Surg; 2010 Jun; 51(6):1498-503. PubMed ID: 20304584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension.
    Itoh T; Nagaya N; Ishibashi-Ueda H; Kyotani S; Oya H; Sakamaki F; Kimura H; Nakanishi N
    Respirology; 2006 Mar; 11(2):158-63. PubMed ID: 16548900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory activation during coronary artery surgery and its dose-dependent modulation by statin/ACE-inhibitor combination.
    Radaelli A; Loardi C; Cazzaniga M; Balestri G; DeCarlini C; Cerrito MG; Cusa EN; Guerra L; Garducci S; Santo D; Menicanti L; Paolini G; Azzellino A; Lavitrano ML; Mancia G; Ferrari AU
    Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2750-5. PubMed ID: 17823365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic inflammation in patients with COPD and pulmonary hypertension.
    Joppa P; Petrasova D; Stancak B; Tkacova R
    Chest; 2006 Aug; 130(2):326-33. PubMed ID: 16899829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
    Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
    Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additive effect of tadalafil and simvastatin on monocrotaline-induced pulmonary hypertension rats.
    Zhang WH; Liu CP; Zhang YJ; Ji YQ; Lu WX; Zeng Q
    Scand Cardiovasc J; 2012 Dec; 46(6):374-80. PubMed ID: 22971207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of simvastatin on systemic inflammatory responses after cardiopulmonary bypass.
    TAMAYO E; ALVAREZ FJ; ALONSO O; BUSTAMANTE R; CASTRODEZA J; SORIA S; LAJO C
    J Cardiovasc Surg (Torino); 2009 Oct; 50(5):687-94. PubMed ID: 19741581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
    Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
    Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
    Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
    Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
    Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
    Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia.
    Szczeklik A; Musiał J; Undas A; Gajewski P; Góra P; Swadźba J; Jankowski M
    J Am Coll Cardiol; 1999 Apr; 33(5):1286-93. PubMed ID: 10193729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT.
    Kawut SM; Bagiella E; Lederer DJ; Shimbo D; Horn EM; Roberts KE; Hill NS; Barr RG; Rosenzweig EB; Post W; Tracy RP; Palevsky HI; Hassoun PM; Girgis RE;
    Circulation; 2011 Jun; 123(25):2985-93. PubMed ID: 21593252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis.
    Tikiz C; Utuk O; Pirildar T; Bayturan O; Bayindir P; Taneli F; Tikiz H; Tuzun C
    J Rheumatol; 2005 Nov; 32(11):2095-101. PubMed ID: 16265685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome.
    Gao XR; Adhikari CM; Peng LY; Guo XG; Zhai YS; He XY; Zhang LY; Lin J; Zuo ZY
    J Pharm Pharmacol; 2009 Nov; 61(11):1505-10. PubMed ID: 19903376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenic and inflammatory biomarkers in the differentiation of pulmonary hypertension.
    Säleby J; Bouzina H; Lundgren J; Rådegran G
    Scand Cardiovasc J; 2017 Oct; 51(5):261-270. PubMed ID: 28776404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease.
    Clavé MM; Maeda NY; Thomaz AM; Bydlowski SP; Lopes AA
    Congenit Heart Dis; 2019 Mar; 14(2):246-255. PubMed ID: 30343508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients.
    Fogari R; Preti P; Zoppi A; Lazzari P; Corradi L; Fogari E; Ciccarelli L; Derosa G
    Eur J Clin Pharmacol; 2006 Oct; 62(10):817-22. PubMed ID: 16896785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.